Covered recipient · General Payments record
OLAKUNLE O AKINBOBOYE
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$27,784.12
132 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,035.96 | 9 |
| Consulting Fee | $9,279.82 | 5 |
| Food and Beverage | $2,454.74 | 116 |
| Education | $13.60 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | $10,086.84 | 6 |
| PFIZER INC. | $6,588.86 | 8 |
| Akcea Therapeutics, Inc. | $3,284.98 | 7 |
| Amgen Inc. | $2,975.00 | 2 |
| Sobi, Inc | $2,682.85 | 5 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $348.84 | 11 |
| Janssen Pharmaceuticals, Inc | $275.98 | 14 |
| Novartis Pharmaceuticals Corporation | $218.23 | 15 |
| AstraZeneca Pharmaceuticals LP | $184.42 | 9 |
| Merck Sharp & Dohme Corporation | $174.15 | 10 |
| SANOFI-AVENTIS U.S. LLC | $140.64 | 8 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $137.72 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $116.97 | 7 |
| DEXCOM, INC. | $112.27 | 5 |
| Abbott Laboratories | $83.30 | 3 |
| Novo Nordisk Inc | $82.49 | 4 |
| Amarin Pharma Inc. | $77.64 | 5 |
| Lilly USA, LLC | $38.83 | 2 |
| Kowa Pharmaceuticals America, Inc. | $35.32 | 2 |
| Currax Pharmaceuticals LLC | $33.01 | 2 |
| Bardy Diagnostics, Inc. | $25.00 | 1 |
| Biogen, Inc. | $24.96 | 1 |
| Esperion Therapeutics, Inc. | $21.32 | 1 |
| ARBOR PHARMACEUTICALS, INC. | $19.68 | 1 |
| Itamar Medical Inc | $14.82 | 1 |
Page 3 of 3; records 101–132 of 132 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
OLAKUNLE O AKINBOBOYE
NPI 1780632844 · CMS profile ID 307931
Allopathic & Osteopathic Physicians / Internal Medicine
LAURELTON, NY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–132 of 132 matching records. This page contains 32 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1780632844?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- OLAKUNLE O AKINBOBOYE, NPI 1780632844, CMS profile ID 307931. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–132 of 132 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780632844?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). OLAKUNLE O AKINBOBOYE, NPI 1780632844, CMS profile ID 307931. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–132 of 132 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780632844?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- OLAKUNLE O AKINBOBOYE, NPI 1780632844, CMS profile ID 307931, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–132 of 132 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1780632844?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
132 matching records · $27,784.12 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–132 of 132.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1.73 | 03/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812580947 | CMS |
| Akcea Therapeutics, Inc. | $1,590.00 | 03/25/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813773931 | CMS |
| PFIZER INC. | $1,500.00 | 03/25/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832501939 | CMS |
| Janssen Pharmaceuticals, Inc | $29.95 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788673855 | CMS |
| PFIZER INC. | $14.93 | 03/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832523227 | CMS |
| Merck Sharp & Dohme Corporation | $21.43 | 03/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848513285 | CMS |
| Akcea Therapeutics, Inc. | $22.78 | 03/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813773927 | CMS |
| Novartis Pharmaceuticals Corporation | $19.32 | 03/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812580945 | CMS |
| Akcea Therapeutics, Inc. | $1,590.00 | 03/15/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813773923 | CMS |
| Abbott Laboratories | $13.95 | 03/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818439357 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.35 | 03/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829619095 | CMS |
| Amarin Pharma Inc. | $13.50 | 03/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815059407 | CMS |
| Currax Pharmaceuticals LLC | $17.03 | 03/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792524851 | CMS |
| Novo Nordisk Inc | $20.86 | 03/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810633313 | CMS |
| Novartis Pharmaceuticals Corporation | $1.77 | 03/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812580943 | CMS |
| Merck Sharp & Dohme Corporation | $15.07 | 02/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848650509 | CMS |
| Akcea Therapeutics, Inc. | $22.78 | 02/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813773919 | CMS |
| Janssen Pharmaceuticals, Inc | $28.05 | 02/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788673861 | CMS |
| Lilly USA, LLC | $17.29 | 02/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818712149 | CMS |
| Alnylam Pharmaceuticals Inc. | $24.61 | 02/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 828527285 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.35 | 02/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829699679 | CMS |
| Amarin Pharma Inc. | $16.88 | 02/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815422175 | CMS |
| Novartis Pharmaceuticals Corporation | $2.62 | 01/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812580941 | CMS |
| Merck Sharp & Dohme Corporation | $18.46 | 01/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848459575 | CMS |
| PFIZER INC. | $28.22 | 01/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832500323 | CMS |
| Abbott Laboratories | $39.61 | 01/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818397561 | CMS |
| Akcea Therapeutics, Inc. | $22.70 | 01/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813773915 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.18 | 01/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829393959 | CMS |
| Alnylam Pharmaceuticals Inc. | $3,690.00 | 01/12/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 828527255 | CMS |
| Novartis Pharmaceuticals Corporation | $13.38 | 01/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812580939 | CMS |
| SANOFI-AVENTIS U.S. LLC | $21.02 | 01/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843483031 | CMS |
| Akcea Therapeutics, Inc. | $22.61 | 01/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813773911 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $295,126.88 | 32 |
| PY2024 | Principal investigator | $338,804.53 | 48 |
| PY2023 | Principal investigator | $175,791.70 | 28 |
| PY2022 | Principal investigator | $156,765.62 | 22 |
| PY2021 | Principal investigator | $62,979.60 | 41 |
| PY2020 | Principal investigator | $133,371.59 | 57 |
| PY2019 | Principal investigator | $183,159.48 | 97 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
32 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,000.00 | 12/01/2025 | Non-covered Recipient Entity Laurelton Heart Specialist PC - MyClinical - PPDS | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508583 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,500.00 | 12/01/2025 | Non-covered Recipient Entity Laurelton Heart Specialist PC - MyClinical - PPDS | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508587 |
| Principal investigator 1 | Eidos Therapeutics, Inc. | $1,843.20 | 11/21/2025 | Non-covered Recipient Entity Laurelton Heart Specialist PC | An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301) | No dispute reported | 06/30/2026 | 1250868577 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,109.00 | 11/19/2025 | Non-covered Recipient Entity Laurelton Heart Specialists PC Ultrasound | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175254780 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $8,000.00 | 11/18/2025 | Non-covered Recipient Entity Queens Heart Institute | Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF) | No dispute reported | 06/30/2026 | 1235994381 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,330.00 | 11/07/2025 | Non-covered Recipient Entity Laurelton Heart Specialists PC Ultrasound | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175254788 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $8,500.00 | 11/05/2025 | Non-covered Recipient Entity Laurelton Heart Specialist PC - MyClinical - PPDS | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508591 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,000.00 | 11/05/2025 | Non-covered Recipient Entity Laurelton Heart Specialist PC - MyClinical - PPDS | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508597 |
| Principal investigator 1 | Eidos Therapeutics, Inc. | $357.00 | 10/31/2025 | Non-covered Recipient Entity Laurelton Heart Specialist PC | An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301) | No dispute reported | 06/30/2026 | 1250868579 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $634.50 | 10/02/2025 | Non-covered Recipient Entity LAURELTON HEART SPECIALIST PC | A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM | No dispute reported | 06/30/2026 | 1246787886 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,595.00 | 09/19/2025 | Non-covered Recipient Entity Laurelton Heart Specialists PC Ultrasound | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175254813 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $3,179.52 | 09/01/2025 | Non-covered Recipient Entity LAURELTON HEART SPECIALIST PC | A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM | No dispute reported | 06/30/2026 | 1246787068 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,590.00 | 08/25/2025 | Non-covered Recipient Entity Laurelton Heart Specialists PC Ultrasound | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175254795 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $634.50 | 07/28/2025 | Non-covered Recipient Entity LAURELTON HEART SPECIALIST PC | A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM | No dispute reported | 06/30/2026 | 1246785782 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,674.00 | 07/23/2025 | Non-covered Recipient Entity Laurelton Heart Specialists PC Ultrasound | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175254772 |
| Principal investigator 1 | Eidos Therapeutics, Inc. | $1,150.00 | 07/22/2025 | Non-covered Recipient Entity Laurelton Heart Specialist PC | A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) | No dispute reported | 06/30/2026 | 1250868581 |
| Principal investigator 1 | Eidos Therapeutics, Inc. | $10,515.00 | 07/22/2025 | Non-covered Recipient Entity Laurelton Heart Specialist PC | A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) | No dispute reported | 06/30/2026 | 1250868583 |
| Principal investigator 1 | Exact Sciences Corporation | $32.50 | 07/02/2025 | Non-covered Recipient Entity MYCLINICAL LLC | Informed Choice Intervention for Colorectal Cancer Screening: COMPASS | No dispute reported | 06/30/2026 | 1244037068 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,524.41 | 06/24/2025 | Non-covered Recipient Entity Queens Heart Institute | Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF) | No dispute reported | 06/30/2026 | 1235994379 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,219.00 | 06/23/2025 | Non-covered Recipient Entity Laurelton Heart Specialists PC Ultrasound | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175254763 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $2,053.08 | 06/20/2025 | Non-covered Recipient Entity LAURELTON HEART SPECIALIST PC | A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOID CARDIOMYOPATHY ATTRCM | No dispute reported | 06/30/2026 | 1246784464 |
| Principal investigator 1 | Janssen Research & Development, LLC | $55,406.00 | 06/20/2025 | Non-covered Recipient Entity Laurelton Heart Specialists PC Ultrasound | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175254821 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $33,051.70 | 05/02/2025 | Non-covered Recipient Entity LAURELTON HEART SPECIALIST, P.C | A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension | No dispute reported | 06/30/2026 | 1185544779 |
| Principal investigator 1 | PFIZER INC. | $1,210.50 | 04/26/2025 | Non-covered Recipient Entity Laurelton Heart Specialist PC | A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE | No dispute reported | 06/30/2026 | 1228795013 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,650.00 | 04/03/2025 | Non-covered Recipient Entity LAURELTON HEART SPECIALIST PC | A randomized, controlled, multicenter, open-label trial comparing a post-discharge care pathway involving aggressive LDL-C management with inclisiran with usual care in patients with a recent acute coronary syndrome | No dispute reported | 06/30/2026 | 1190308308 |
| Principal investigator 1 | AstraZeneca UK Limited | $78,229.60 | 03/25/2025 | Non-covered Recipient Entity LAURELTON HEART SPECIALIST, P.C | A Phase IIb Two cohort Randomised Placebo controlled Double blind Multicentre Dose ranging Study of AZD5462 in Stable Patients with Chronic Heart Failure | No dispute reported | 06/30/2026 | 1185544781 |
| Principal investigator 1 | PFIZER INC. | $12,000.00 | 03/04/2025 | Non-covered Recipient Entity Laurelton Heart Specialist PC | A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE | No dispute reported | 06/30/2026 | 1228794694 |
| Principal investigator 1 | Exact Sciences Corporation | $149.50 | 02/28/2025 | Non-covered Recipient Entity MYCLINICAL LLC | Informed Choice Intervention for Colorectal Cancer Screening: COMPASS | No dispute reported | 06/30/2026 | 1244037063 |
| Principal investigator 1 | PFIZER INC. | $3,062.24 | 02/28/2025 | Non-covered Recipient Entity Laurelton Heart Specialist PC | A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE | No dispute reported | 06/30/2026 | 1228759029 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $10,557.93 | 01/22/2025 | Non-covered Recipient Entity QUEENS HEART INSTITUTE | This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio | No dispute reported | 06/30/2026 | 1185544777 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,527.00 | 01/22/2025 | Non-covered Recipient Entity Laurelton Heart Specialists PC Ultrasound | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175254805 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $19,841.70 | 01/17/2025 | Non-covered Recipient Entity QUEENS HEART INSTITUTE | A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension | No dispute reported | 06/30/2026 | 1185544775 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2025 | Amount invested | $106,246.57 | 1 |
| PY2025 | Value of interest | $131,167.50 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
1 record · PY2025
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2025 | VivaQuant Inc, dba Rhythm Express | $106,246.57 | $131,167.50 | Common stock (certificated), 34,978 shares acquired on Nov 11, 2021 at $3.0375 per share; current price per share $3.75 | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1250896541 |